[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc (LSE/NYSE: HLN) filed a Form 6-K to report activity under the second tranche of its share-buyback programme announced on 31 July 2025. On 7 August 2025 the company purchased 1,330,960 ordinary shares (nominal £0.01) for cancellation on the London Stock Exchange at prices between 346.5p – 354.4p, delivering a volume-weighted average price of 351.6198p.

Post-settlement, Haleon’s registered share capital stands at 8,980,592,548 ordinary shares, of which 3,880,205 are held in treasury, leaving 8,976,712,343 voting shares outstanding. A detailed trade log is available via the RNS link and on the company’s investor website. No other material financial information or guidance is provided in this filing.

Positive

• Continuation of share-buyback programme demonstrates ongoing commitment to shareholder returns.
• Immediate cancellation of repurchased shares avoids treasury stock overhang and marginally raises EPS and voting power.

Negative

• None.

Insights

Equity Research Analyst

TL;DR – Small buyback; negligible EPS impact.

The repurchase of 1.33 M shares equals roughly 0.015% of the 8.98 B share count, so the immediate financial effect is immaterial. Still, it confirms management’s commitment to capital returns and may signal confidence in intrinsic value. Because Haleon discloses no cost figures beyond VWAP, it is unclear how the programme is funded or its total authorised size. Overall impact on valuation and leverage appears de minimis.

Corporate Governance Specialist

TL;DR – Routine cancellation maintains dilution discipline.

Cancelling the shares prevents future dilution and marginally improves voting power for remaining shareholders. The filing satisfies UK Market Abuse Regulation requirements by providing a trade-by-trade breakdown link, reflecting sound transparency practices. No red flags noted.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	08 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

08 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,330,960 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	07 August 2025	07 August 2025	07 August 2025
Number of Shares purchased:	1,330,960	-	-
Highest price paid per Share (p):	354.4000	-	-
Lowest price paid per Share (p):	346.5000	-	-
Volume weighted average price paid per Share (p):	351.6198	-	-

Following the settlement of the above, the Company's registered share capital is 8,980,592,548 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,976,712,343 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below: 

http://www.rns-pdf.londonstockexchange.com/rns/4954U_1-2025-8-7.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.  

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 08, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many Haleon (HLN) shares were repurchased on 7 Aug 2025?

The company bought 1,330,960 ordinary shares for cancellation.

What price did Haleon pay for its share buyback?

Prices ranged from 346.5p to 354.4p with a volume-weighted average of 351.6198p per share.

How many voting shares does Haleon now have outstanding?

After settlement, Haleon has 8,976,712,343 ordinary shares with voting rights.

Where can investors find the full trade breakdown for the repurchase?

A detailed log is available at the RNS link provided: http://www.rns-pdf.londonstockexchange.com/rns/4954U_1-2025-8-7.pdf.

Does the filing provide any earnings or guidance updates?

No. The Form 6-K is limited to disclosure of the share buyback transaction.